close
MENU
Hot Topic NBR Focus: GMO
Hot Topic NBR Focus: GMO
On the Record
5 mins to read

No comment, no accountability

OPINION: Pharmac’s governance yet to respond to review.

NBR columnist Rachel Smalley speaks with Maria Slade

Pharmac, our monopolistic drug-buying agency, is yet to speak to the media about the much-awaited independent Review in June, that looked into its performance.

The review was released by Minister Andrew Little and while he spoke to its findings at the time including some of the key criticisms

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

NZ$399.00 / yearly

Offer ends July 31st

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
No comment, no accountability
On the Record,
95150
true